Mechanisms of Vaccine Induced Susceptibility to Viral Infection

35 concepts23 papers1 proposal

The fundamental goal of vaccination is simple: introduce a harmless component of a pathogen to train the immune system, ensuring that subsequent exposure triggers rapid, protective clearance. However, a troubling paradox has emerged across multiple viral fields. Under specific biological conditions, the very immune responses or delivery mechanisms intended to protect a host can instead act as a gateway, making the host more susceptible to infection or exacerbating disease severity.

This phenomenon operates primarily through two distinct mechanisms: substrate expansion (providing more target cells for the virus to infect) and receptor exploitation (using sub-optimal antibodies to actively pull the virus into host cells). Understanding why these pathways occur is essential for engineering the next generation of safe vaccines and immunotherapies.

The Substrate Problem: Vector-Induced Target Cell Activation

To understand how a vaccine can increase infection risk, we must look at viruses that specifically target immune cells, such as HIV. HIV preferentially infects activated CD4+ T cells. When a vaccine uses a viral vector—such as a recombinant adenovirus 5 (rAd5)—to deliver an antigen, it does not just stimulate an antigen-specific response; it also triggers a localized or generalized wave of immune activation.

If this immune activation expands the pool of vulnerable CD4+ T cells at the site of exposure, it inadvertently provides the virus with a higher density of replication substrates. As shown by Zoe Moodie et al. in the Phambili Phase 2b trial (Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men), certain vaccine platforms significantly increased HIV-1 acquisition among vaccinated men. A participant-level meta-analysis by Yunda Huang et al. (Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials) confirmed that this risk was highly dependent on the specific vaccine regimen: while the standalone MRKAd5 vector increased susceptibility, a DNA-prime/rAd5-boost regimen did not, indicating that the biological environment created by the delivery system dictates the outcome.

Why does this happen at a cellular level? The authors discovered that nonspecific interferon-gamma (IFN-γ) secretion—often dismissed as background noise—strongly predicted increased infection risk by reflecting a generalized state of immune activation that recruits target cells to mucosal exposure sites (Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study).

Similarly, Carolina Campos Lima Moreira et al. (P173 Investigating varicella-zoster virus-specific T cells through the lenses of HIV) highlighted a fundamental conflict in vaccine design: achieving high immunogenicity often upregulates activation markers like HLA-DR on CD4+ T cells, which simultaneously renders them highly vulnerable to viral entry. This vulnerability is mirrored in natural co-infections; for instance, Shi Zou et al. (The Role of CD4+CD8+ T Cells in HIV Infection With Tuberculosis) found that the expansion of CD4+CD8+ T cells during tuberculosis co-infection upregulates the CCR5 co-receptor, fueling primary HIV replication by providing more cellular entry points.

Even when a vaccine exerts protective pressure against a perfectly matched strain, this substrate expansion can backfire against mismatched variants. A sieve analysis by Allan C. deCamp et al. (Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120) demonstrated that while the HVTN 505 vaccine pressured the virus at the CD4 binding site, the vector-induced immune activation paradoxically increased the risk of acquiring mismatched viral strains. This delicate balance between target cell expansion and viral clearance is a known challenge in viral dynamics; mathematical modeling by Rodolphe Thiébaut et al. (Modeles mathematiques dynamiques pour la medecine personnalisee) shows that expanding healthy target cell populations without sufficient viral inhibition inevitably triggers a viral rebound.

The Receptor Problem: Antibody-Dependent Enhancement

The second major pathway of paradoxical enhancement does not rely on activating target cells, but rather on the structural behavior of the antibodies themselves. This is known as Antibody-Dependent Enhancement (ADE).

When a host encounters a virus in the presence of sub-neutralizing or cross-reactive antibodies, these antibodies can act as a bridge rather than a barrier. Instead of neutralizing the virus by blocking its receptor-binding domain, the antibody binds weakly to the virus while its constant region (Fc tail) binds to Fc receptors on immune cells. This effectively transforms the immune cell's own defense mechanism into an entry portal for the pathogen.

[Virus] === (Sub-neutralizing Antibody) === [Fc Receptor] ===> [Immune Cell Entry]

In multi-serotype pathogens like Dengue, pre-existing antibodies from a primary infection fail to neutralize a secondary serotype, instead facilitating its entry into host cells and causing significantly higher viral loads (Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine). This cross-reactive risk complicates multi-pathogen vaccine design, such as chimeric flavivirus candidates (An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens).

For respiratory viruses like SARS-CoV-2, the molecular mechanics of ADE require highly specific structural configurations. Shuang Wang et al. (Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction) demonstrated that ADE of SARS-CoV-2 pseudoviral infection requires a bivalent interaction—where both arms of the antibody engage the virus—and specifically targets the FcγRIIB receptor on B cells.

While this raised significant safety concerns during vaccine development (A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity; Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants), further work by Xun Wang et al. (In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG) showed that in vitro ADE could be abolished by the presence of excess human IgG or by modifying the antibody's Fc region, suggesting that competitive binding in vivo may mitigate some of these risks.

Furthermore, the host's innate antiviral defenses can create a feedback loop that exacerbates this susceptibility. For instance, Saskia Trump (COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis) discovered that interferon signaling in the airway epithelium can triple the expression of viral entry receptors in secretory cells, showing how the body's primary defense pathway can inadvertently facilitate further viral entry.

Engineering Around the Paradox

Recognizing these mechanisms has allowed researchers to shift from broad immunogenicity goals toward precise molecular engineering to bypass these vulnerabilities.

To solve the substrate problem in HIV vaccines, researchers are developing "biologically quiet" vectors. Catia Perciani et al. (Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation) demonstrated that a live attenuated varicella-zoster virus (VZV) vector successfully avoids inducing mucosal CD4+ T cell activation, remaining below the critical 20% safety threshold established in their clinical trial framework (Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine). Alternatively, combining a standalone vaccine with antiretroviral prophylaxis can suppress the initial viral replication fueled by vaccine-induced susceptibility, as demonstrated by Roger Le Grand et al. (Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates).

To solve the receptor problem in antibody therapies and vaccines, researchers modify the structural components that interact with Fc receptors. Shuang Wang et al. (Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys) engineered a potent monoclonal antibody (MW05) with a specific "LALA" mutation in the Fc region, completely eliminating Fc-receptor binding and abolishing the risk of ADE while maintaining full neutralizing efficacy. Similarly, validating the absolute absence of ADE in animal models remains a core safety benchmark for therapeutic cocktails like REGN-COV2 (REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters).

Finally, vaccine platforms are shifting away from antibody induction entirely when the risk of ADE is too high. Alix Miauton et al. (Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study) evaluated a synthetic nanoparticle vaccine for Dengue designed exclusively to prime CD8+ T-cell responses, completely avoiding the production of sub-neutralizing antibodies. On the antibody side, Jay Lubow et al. (Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses) identified broadly neutralizing IgA antibody isotypes against flaviviruses, which utilize different mucosal clearance pathways and do not engage the classic IgG-Fc receptor pathways that drive enhancement.

History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_antibody_dependent_enhancement_ac33b970,
  title = {antibody-dependent enhancement},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/antibody-dependent-enhancement/rdr_ac33b970e87243608f35e4c36686cc95},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_antibody_dependent_enhancement_ac33b970_v1,
  title = {antibody-dependent enhancement},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/antibody-dependent-enhancement/rdr_ac33b970e87243608f35e4c36686cc95/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake